PDS Biotechnology Reports Financial Results for the Second Quarter 2020 and Provides Business Update
(WorldNews Environment)

FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company`s proprietary Versamune® T-cell activating technology, today announced its financial results for the second quarter ended June 30, 2020 and provided a business update. Second Quarter 2020 and Recent Business Highlights Announced publication of PDS0101 triple combination preclinical study by the National Cancer Institute; Initiated Phase 2 clinical trial of PDS0101 triple combination, led by the National Cancer Institute, for the treatment of advanced human...